Onconova Therapeutics (NASDAQ: ONTX) Decreased to Hold at Zacks Investment Research

Onconova Therapeutics (NASDAQ: ONTX) was devalued by Zacks  from a “get” rating to a “hold” ranking in a research note released to investors on Thursday, records.

According to Zacks, “Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical business. It focuses on uncovering and also establishing little particle medicine candidates to treat cancer. The Business‘s items under various stages of growth consist of Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Numerous other equities research experts likewise lately discussed the firm. Noble Financial editioned a “get” score as well as provided a $11.00 price objective on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their price target on Onconova Therapeutics from $29.00 to $12.00 and also established a “buy” rating on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened up at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and a twelve month high of $28.95. Business has a 50 day relocating typical price of $2.90 as well as a two-hundred day relocating average price of $4.16. The firm has a market cap of $46.76 million, a P/E proportion of -1.82 and also a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last launched its quarterly profits results on Thursday, November 11th. The biopharmaceutical company reported ($ 0.22) revenues per share for the quarter, topping experts’ consensus quotes of ($ 0.33) by $0.11. Onconova Therapeutics had a negative return on equity of 59.78% as well as a negative web margin of 8,294.27%. The firm had profits of $0.06 million during the quarter, compared to the agreement estimate of $0.06 million. During the same quarter in the prior year, the firm uploaded ($ 0.45) EPS. As a group, research experts anticipate that Onconova Therapeutics will certainly publish -1.18 EPS for the present year.

A variety of hedge funds have actually recently dealt shares of ONTX. GSA Funding Allies LLP bought a new setting in Onconova Therapeutics during the third quarter worth $922,000. Hudson Bay Funding Administration LP acquired a brand-new setting in shares of Onconova Therapeutics in the third quarter worth $635,000. Pura Vida Investments LLC bought a brand-new position in shares of Onconova Therapeutics in the third quarter worth $575,000. CVI Holdings LLC purchased a brand-new placement in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Finally, Dimensional Fund Advisors LP bought a new placement in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds as well as other institutional financiers have 13.36% of the business’s stock.

Regarding Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company, which participates in the recognition and development of oncology therapeutics. It concentrates on finding and developing tiny molecule drug prospects to deal with cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 as well as is headquartered in Newtown, PA

. Obtain a free copy of the Zacks research record on Onconova Therapeutics (ONTX).

For more information about research offerings from Zacks Investment Research, visit

This immediate news alert was generated by narrative science modern technology and monetary information from Market in order to give readers with the fastest and also most accurate coverage. This tale was reviewed by Market’s editorial team before publication. 



Before you think about Onconova Therapeutics, you’ll wish to hear this.

Market keeps an eye on Wall Street’s premier as well as ideal doing research experts as well as the stocks they suggest to their customers daily. Market has actually recognized the five stocks that top analysts are silently murmuring to their customers to buy currently prior to the more comprehensive market catches on … and also Onconova Therapeutics wasn’t on the list.

While Onconova Therapeutics presently has a “Buy” rating amongst analysts, top-rated experts believe these five stocks are much better buys.

Comments Off on Onconova Therapeutics (NASDAQ: ONTX) Decreased to Hold at Zacks Investment Research